Deng, Kaiwen
Li, Yueming
Zhang, Hanrui
Wang, Jian
Albin, Roger L.
Guan, Yuanfang http://orcid.org/0000-0001-8275-2852
Funding for this research was provided by:
American Parkinson Disease Association
Eli Lilly and Company
Michael J. Fox Foundation for Parkinson’s Research
Article History
Received: 26 August 2021
Accepted: 23 December 2021
First Online: 17 January 2022
Competing interests
: The authors declare the following competing interests: J.W. is a current Eli Lilly and Company employee. Y.G. serves as the scientific advisor for Eli Lilly and Company on the tapping part of this study. R.L.A. serves on the DSMBs for the COMPASS and PASSPORT trials (Biogen), the M-STAR trial (Biohaven), and the Signal-AD trial (Vaccinex). R.L.A. has received consulting fees from the Michael J. Fox Foundation and Takeda. The remaining authors declare no competing interests.